ClinicalTrials.gg
CompletedNCT02255422Updated Jun 5, 2025Results posted

RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR

A Phase 2 interventional study of Omaveloxolone capsules, 2.5 mg and omaveloxolone capsules, 5 mg in MItochondrial Myopathies, sponsored by Biogen. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Biogen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Mitochondrial Myopathies with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Mitochondrial Myopathies · United States.

Enrollment
5th of 12
53 · median 50
Started
2015
with 1 other
Phase 2
5 of 19
none open now
Registered
4th of 19
by date
Lead sponsor
1 of 19
Biogen

Among the 19 studies in Mitochondrial Myopathies with a site in United States, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2015, is one of 5 in phase 2, and was the 4th registered.

Mitochondrial Myopathies

46 studies on the registry are indexed under Mitochondrial Myopathies; 14 are open to participants now.

Browse Mitochondrial Myopathies studies →

Open to participants now

6 of the 19 studies in Mitochondrial Myopathies with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Mitochondrial Myopathies studies recruiting now, 8 (62%) set no upper age limit and 4 (31%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Mitochondrial Myopathies with a site in United States, or all of them as a file.
02

Study summary

Mitochondrial myopathies are a multisystemic group of disorders that are characterized by a wide range of biochemical and genetic mitochondrial defects and variable modes of inheritance. Currently there are no effective treatments for this disease. Despite the heterogeneous myopathy phenotypes, a unifying feature of mitochondrial myopathies is that the pathogenic mtDNA mutations and/or nuclear mutations of the electron transport chain invariably lead to dysfunctional mitochondrial respiration. This reduction in mitochondrial respiration leads to a reduced ability to produce cellular adenosine triphosphate (ATP), often resulting in muscle weakness, exercise intolerance, and fatigue in patients with mitochondrial myopathies.

RTA 408 is a potent activator of Nrf2 and inhibitor of NF κB (nuclear factor kappa-light-chain-enhancer of activated B cells), and thus induces an antioxidant and anti-inflammatory phenotype. Several lines of evidence suggest that Nrf2 activation can increase mitochondrial respiration and biogenesis. Collectively, available data suggest that the ability of RTA 408 to activate Nrf2 and induce its target genes could potentially improve muscle function, oxidative phosphorylation, antioxidant capacity, and mitochondrial biogenesis in patients with mitochondrial myopathies.

This study will be a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in patients with mitochondrial myopathies.

03

Conditions studied

  • MItochondrial Myopathies

Keywords

  • omaveloxolone
  • RTA 408 capsules
  • mitochondrial myopathies
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have mitochondrial myopathy as evidenced by the following 2 criteria (must meet both):

    1. Have a history of exercise intolerance with or without weakness and/or progressive exercise intolerance (in which modest exercise typically provokes heaviness, weakness, aching of active muscles, or tachycardia)
    2. Have a known primary mitochondrial DNA mutation or a nuclear DNA defect that is associated with reduced activity of at least 1 mitochondrially encoded respiratory chain complex
  2. Be male or female and ≥18 years of age and ≤75 years of age
  3. Have no changes to exercise regimen within 30 days prior to Study Day 1 and be willing to remain on the same exercise regimen during the 16-week study period
  4. Have the ability to complete maximal exercise testing
  5. Have a peak workload during maximal exercise testing of ≤ 1.5 W/kg
  6. Be able to swallow capsules

Exclusion criteria

Exclusion Criteria:

  1. Have uncontrolled diabetes ( >11.0%)
  2. Have B-type natriuretic peptide level >200 pg/mL
  3. Have a history of left-sided heart disease and/or clinically significant cardiac disease
  4. Have known active fungal, bacterial, and/or viral infection, including or hepatitis virus (B or C)
  5. Have known or suspected active drug or alcohol abuse
  6. Have clinically significant abnormalities of clinical hematology or biochemistry, including but not limited to elevations greater than 1.5 times the of , alanine aminotransferase, or creatinine
  7. Have any abnormal laboratory test value or serious pre-existing medical condition that, in the opinion of the investigator, would put the patient at risk by study enrollment
  8. Have taken any of the following drugs within 7 days prior to Study Day 1 or plan to take any of these drugs during the time of study participation:

    1. Sensitive substrates for cytochrome P450 2C8 or 3A4 (e.g., repaglinide, midazolam, sildenafil)
    2. Substrates for p-glycoprotein transporter (e.g., ambrisentan, digoxin)
  9. Have participated in any other interventional clinical study within 30 days prior to Study Day 1
  10. Have a cognitive impairment that may preclude ability to comply with study procedures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    omaveloxolone Capsules 2.5 mg and 5 mg

    omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks

    Drug: Omaveloxolone capsules, 2.5 mg · Drug: omaveloxolone capsules, 5 mg

  • Experimental
    omaveloxolone Capsules 10 mg

    omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks

    Drug: omaveloxolone capsules, 10 mg

  • Placebo comparator
    Placebo Capsules

    Placebo capsules taken orally once daily for 12 weeks

    Drug: Placebo capsules

  • Experimental
    omaveloxolone Capsules 20 mg

    omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.

    Drug: omaveloxolone capsules, 20 mg

  • Experimental
    omaveloxolone Capsules 40 mg

    omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.

    Drug: omaveloxolone capsules, 40 mg

  • Experimental
    omaveloxolone Capsules 80 mg

    omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.

    Drug: omaveloxolone capsules, 80 mg

  • Experimental
    omaveloxolone Capsules 160 mg

    omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.

    Drug: omaveloxolone capsules, 160 mg

Interventions

  • DrugOmaveloxolone capsules, 2.5 mg

    Also known as: RTA 408 Capsules 2.5 mg

  • Drugomaveloxolone capsules, 5 mg

    Also known as: RTA 408 capsules, 5 mg

  • Drugomaveloxolone capsules, 10 mg

    Also known as: RTA 408, 10 mg

  • DrugPlacebo capsules
  • Drugomaveloxolone capsules, 20 mg

    Also known as: RTA 408 capsules, 20 mg

  • Drugomaveloxolone capsules, 40 mg

    Also known as: RTA 408 capsules, 40 mg

  • Drugomaveloxolone capsules, 80 mg

    Also known as: RTA 408 capsules, 80 mg

  • Drugomaveloxolone capsules, 160 mg

    Also known as: RTA 408 capsules, 160 mg

06

What researchers measure

Primary outcomes

  1. Change of Peak Workload (in Watts/kg) During Exercise Testing

    Cycle ergometry using a stationary recumbent bike was used to conduct maximal exercise testing. Peak work is defined as the workload at which patients reach maximal volition (defined as an inability to continue to exercise due to exhaustion). Change of peak workload during exercise testing was measured at baseline, Week 4, and Week 12. Change from baseline at Week 12 reported.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in 6-minute Walk Test (6MWT) Distance

    Patients were instructed to walk as far as they could along a marked path for 6 minutes. Distance walked was measured. If patients used a cane or walking assist device at Screening, the same walking assist device was to be used for all 6MWT assessments.

    Time frame: 6MWT was assessed at Week 4, Week 8, and Week 12 and compared to baseline

07

Results

Posted Sep 17, 2020

Participant flow

First patient enrolled 5-May-2015, last patient completed 30-Nov-2017

Participant flow — Overall Study
MilestonePlaceboOmaveloxolone Capsules 2.5 and 5 mgOmaveloxolone Capsules 10 mgOmaveloxolone Capsules 20 mgOmaveloxolone Capsules 40 mgOmaveloxolone Capsules 80 mgOmaveloxolone Capsules 160 mg
Started136666610
Completed13656668
Not completed0010002
Withdrew: Withdrawal by subject0000002
Withdrew: Lost to follow-up0010000

Outcome measures

PrimaryChange of Peak Workload (in Watts/kg) During Exercise Testing

Cycle ergometry using a stationary recumbent bike was used to conduct maximal exercise testing. Peak work is defined as the workload at which patients reach maximal volition (defined as an inability to continue to exercise due to exhaustion). Change of peak workload during exercise testing was measured at baseline, Week 4, and Week 12. Change from baseline at Week 12 reported.

Time frame:
12 weeks
Reported as:
Least squares mean · Watts/kg
Change of Peak Workload (in Watts/kg) During Exercise Testing
Watts/kgPlaceboOmaveloxolone Capsules 2.5 and 5 mgOmaveloxolone Capsules 10 mgOmaveloxolone Capsules 20 mgOmaveloxolone Capsules 40 mgOmaveloxolone Capsules 80 mgOmaveloxolone Capsules 160 mg
Change of Peak Workload (in Watts/kg) During Exercise Testing0.0090 ± 0.03880.020 ± 0.0544-0.0300 ± 0.05440.1050 ± 0.0596-0.0520 ± 0.0544-0.0660 ± 0.05440.0020 ± 0.0465
Statistical analysis
  • Placebo vs Omaveloxolone Capsules 2.5 and 5 mg vs Omaveloxolone Capsules 10 mg vs Omaveloxolone Capsules 20 mg vs Omaveloxolone Capsules 40 mg vs Omaveloxolone Capsules 80 mg vs Omaveloxolone Capsules 160 mg · Mixed Models Analysis · p = 0.7321 (P-Value relates to difference in change in peak work from baseline relative to placebo for all doses pooled. Statistical significance was defined as p\<0.05) · Ls mean difference (net): -0.015 · 95% CI -0.1051 to 0.0743Null hypothesis: wk 12 mean change from baseline (\[μ RTA 408\] - \[μ Placebo\]) in peak work = 0 w/kg. Positive change from baseline suggests improvement
SecondaryChange in 6-minute Walk Test (6MWT) Distance

Patients were instructed to walk as far as they could along a marked path for 6 minutes. Distance walked was measured. If patients used a cane or walking assist device at Screening, the same walking assist device was to be used for all 6MWT assessments.

Time frame:
6MWT was assessed at Week 4, Week 8, and Week 12 and compared to baseline
Reported as:
Least squares mean · Meters
Change in 6-minute Walk Test (6MWT) Distance
MetersPlaceboOmaveloxolone Capsules 2.5 and 5 mgOmaveloxolone Capsules 10 mgOmaveloxolone Capsules 20 mgOmaveloxolone Capsules 40 mgOmaveloxolone Capsules 80 mgOmaveloxolone Capsules 160 mg
Week 440.462 ± 10.053919.333 ± 14.965818.2500 ± 14.9658-9.2000 ± 16.3942-11.6670 ± 14.96589.9170 ± 14.965810.8330 ± 12.2195
Week 824.923 ± 9.938112.865 ± 15.737433.9170 ± 15.141813.8000 ± 16.587011.0000 ± 15.141817.5830 ± 15.141828.9440 ± 12.3633
Week 1229.846 ± 12.927617.167 ± 19.651917.7500 ± 19.651928.2000 ± 21.5275-7.833 ± 19.65196.2500 ± 19.65198.5710 ± 16.4721
Statistical analysis
  • Placebo vs Omaveloxolone Capsules 2.5 and 5 mg vs Omaveloxolone Capsules 10 mg vs Omaveloxolone Capsules 20 mg vs Omaveloxolone Capsules 40 mg vs Omaveloxolone Capsules 80 mg vs Omaveloxolone Capsules 160 mg · Mixed Models Analysis · p = 0.0060 (P-value comparison is for difference in change in six minute walk distance from baseline within each dosage group relative to placebo. Statistical significance defined as p\<0.05.) · Ls mean difference (net): -33.448 · 95% CI -56.855 to -10.042The change from baseline in 6MWT was analyzed using the same MMRM model used for the primary efficacy endpoint. Analysis visits 0, 4, 8 and 12 used.
  • Placebo vs Omaveloxolone Capsules 2.5 and 5 mg vs Omaveloxolone Capsules 10 mg vs Omaveloxolone Capsules 20 mg vs Omaveloxolone Capsules 40 mg vs Omaveloxolone Capsules 80 mg vs Omaveloxolone Capsules 160 mg · Mixed Models Analysis · p = 0.7325 (Statistical significance was defined as p\<0.05. The p-value comparison is for the difference in change in 6MWD from baseline within each dosage group relative to placebo.) · Ls mean difference (net): -3.963 · 95% CI -27.133 to 19.207The change from baseline in 6MWT was analyzed using the same MMRM model used for the primary efficacy endpoint. Analysis visits 0, 4, 8 and 12 used.
  • Placebo vs Omaveloxolone Capsules 2.5 and 5 mg vs Omaveloxolone Capsules 10 mg vs Omaveloxolone Capsules 20 mg vs Omaveloxolone Capsules 40 mg vs Omaveloxolone Capsules 80 mg vs Omaveloxolone Capsules 160 mg · Mixed Models Analysis · p = 0.2210 (Statistical significance was defined as p\<0.05. The p-value comparison is for the difference in change in 6MWD from baseline within each dosage group relative to placebo.) · Ls mean difference (net): -18.594 · 95% CI -48.739 to 11.550The change from baseline in 6MWT was analyzed using the same MMRM model used for the primary efficacy endpoint. Analysis visits 0, 4, 8 and 12 used.

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/13 (0%)1/13 (7.7%)11/13 (84.6%)
Omaveloxolone Capsules 2.5 and 5 mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Omaveloxolone Capsules 10 mg0/6 (0%)1/6 (16.7%)6/6 (100%)
Omaveloxolone Capsules 20 mg0/6 (0%)0/6 (0%)6/6 (100%)
Omaveloxolone Capsules 40 mg0/6 (0%)1/6 (16.7%)6/6 (100%)
Omaveloxolone Capsules 80 mg0/6 (0%)1/6 (16.7%)4/6 (66.7%)
Omaveloxolone Capsules 160 mg0/10 (0%)1/10 (10%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventPlaceboOmaveloxolone Capsules 2.5 and 5 mgOmaveloxolone Capsules 10 mgOmaveloxolone Capsules 20 mgOmaveloxolone Capsules 40 mgOmaveloxolone Capsules 80 mgOmaveloxolone Capsules 160 mg
Wide complex tachycardiaCardiac disorders0/130/61/60/60/60/60/10
Optic neuritisNervous system disorders0/130/60/60/61/60/60/10
Right sided hemiparesisNervous system disorders0/130/60/60/61/60/60/10
Exacerbated fatigueGeneral disorders0/130/60/60/60/61/60/10
Atrioventricular dissociationCardiac disorders0/130/60/60/60/60/61/10
Ventricular tachycardiaCardiac disorders0/130/60/60/60/60/61/10
Tonic epileptic seizureNervous system disorders1/130/60/60/60/60/60/10
Most frequent other events
Showing 10 of 106
Most frequent other events
EventPlaceboOmaveloxolone Capsules 2.5 and 5 mgOmaveloxolone Capsules 10 mgOmaveloxolone Capsules 20 mgOmaveloxolone Capsules 40 mgOmaveloxolone Capsules 80 mgOmaveloxolone Capsules 160 mg
MyalgiaMusculoskeletal and connective tissue disorders0/130/64/60/60/60/60/10
FatigueGeneral disorders4/130/63/60/60/61/61/10
DiarrhoeaGastrointestinal disorders3/131/61/62/61/61/62/10
Pain in extremityMusculoskeletal and connective tissue disorders1/132/60/60/60/60/61/10
HeadacheNervous system disorders0/131/61/62/60/60/61/10
DizzinessNervous system disorders1/130/62/60/61/60/60/10
Upper respiratory tract infectionInfections and infestations2/131/60/61/61/60/63/10
Back painMusculoskeletal and connective tissue disorders3/130/60/60/60/60/61/10
NauseaGastrointestinal disorders1/130/61/61/60/60/62/10
VomitingGastrointestinal disorders1/130/60/61/60/60/62/10

Baseline characteristics

All 53 patients were included in the baseline population

Age, Continuous
Age, Continuous(Years)PlaceboOmaveloxolone Capsules 2.5 and 5 mgOmaveloxolone Capsules 10 mgOmaveloxolone Capsules 20 mgOmaveloxolone Capsules 40 mgOmaveloxolone Capsules 80 mgOmaveloxolone Capsules 160 mgTotal
Mean41.1 ± 11.8652.3 ± 9.6149.8 ± 14.0545.5 ± 14.0845.2 ± 4.7130.7 ± 10.2539.8 ± 15.2742.9 ± 13.01
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOmaveloxolone Capsules 2.5 and 5 mgOmaveloxolone Capsules 10 mgOmaveloxolone Capsules 20 mgOmaveloxolone Capsules 40 mgOmaveloxolone Capsules 80 mgOmaveloxolone Capsules 160 mgTotal
Female913454632
Male453212421
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboOmaveloxolone Capsules 2.5 and 5 mgOmaveloxolone Capsules 10 mgOmaveloxolone Capsules 20 mgOmaveloxolone Capsules 40 mgOmaveloxolone Capsules 80 mgOmaveloxolone Capsules 160 mgTotal
Hispanic or Latino20100036
Not Hispanic or Latino1165666747
Unknown or Not Reported00000000
08

Study locations

9 sites
  • UCLA
    Los Angeles, California 90095, United States
  • Mass General Hospital
    Boston, Massachusetts 02114, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Insitute for Exercise & Environmental Medicine
    Dallas, Texas 75231, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Texas Medical School at Houston
    Houston, Texas 77030, United States
  • Neuromuscular Clinic, Rigshospitalet, University of Copenhagen
    Copenhagen, DK-2100, Denmark
09

References and documents

Publications

  • Madsen KL, Buch AE, Cohen BH, Falk MJ, Goldsberry A, Goldstein A, Karaa A, Koenig MK, Muraresku CC, Meyer C, O'Grady M, Scaglia F, Shieh PB, Vockley J, Zolkipli-Cunningham Z, Haller RG, Vissing J. Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial. Neurology. 2020 Feb 18;94(7):e687-e698. doi: 10.1212/WNL.0000000000008861. Epub 2020 Jan 2. PubMed 31896620 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2015 to primary completion in Nov 2017, 29 months.

Results were first posted in Sep 2020, 2 years 10 months after primary completion. A results delay was requested in Jul 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2014
First posted
Oct 2, 2014
StartActual
May 5, 2015
Primary completionActual
Nov 2, 2017
CompletionActual
Nov 30, 2017
Results delay requested
Jul 16, 2018
Results first posted
Sep 17, 2020
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02255422
Lead sponsor
Biogen
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Oct 2, 2014
Start date
May 5, 2015
Primary completion
Nov 2, 2017
Completion
Nov 30, 2017
Results posted
Sep 17, 2020
Last update
Jun 5, 2025

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion